Sanofi Reports the US FDA’s Acceptance & Priority Review of Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis
Shots:
- The US FDA has accepted NDA & granted priority review to tolebrutinib for nrSPMS & slowing disability progression independent of relapse (PDUFA: Sep 28, 2025); MAA is under EMA review
- Submission was backed by P-III trials, incl. HERCULES for nrSPMS & GEMINI 1 & 2 for relapsing MS, along with clinical & preclinical data supporting tolebrutinib’s MoA while also aligning with the hypothesis that smoldering neuroinflammation is a key MS process & major driver of disability accumulation
- Additionally, Tolebrutinib is being evaluated in an ongoing P-III (PERSEUS) trial for primary progressive MS, with results anticipated in H2’25
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi to Acquire Dren Bio’s Bispecific Antibody DR-0201 for ~$1.9B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
